
EV627049635US JC10 Rec'd PCT/PTO 16 JUN 2005



PTO-1390 (Rev. 12-2004)
d for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TR	ANSMITTAL LETTER TO	ATTTORNEY'S DOCKET NUMBER								
	DESIGNATED/ELECTED	100725-48 (KGB)								
CON	ICERNING A SUBMISSION	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/535,522								
	TIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
	22003/012941	19 November 2003 (19.11.2003)	19 November 2002 (19.11.2002)							
TITLE OF Use of s	TITLE OF INVENTION Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases									
APPLICANT(S) FOR DO/EO/US Alexander STEINKASSERER, Matthias LECHMANN, and Elisabeth ZINSER										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1.	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.									
3 🔲	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
4. 📙	The US has been elected (Article 31).									
5.	A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
	a. is attached hereto (required only if not communicated by the International Bureau).									
	b. has been communicated by the International Bureau.									
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
	a. Lis attached hereto.									
	b. La has been previously submitted under 35 U.S.C. 154(d)(4).									
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))									
	a. are attached hereto (required only if not communicated by the International Bureau).									
	b. Have been communicated by the International Bureau.									
	c. A have not been made; however, the time limit for making such amendments has NOT expired.									
	d. have not been made and will not be made.									
8.	An earth or degleration of the inventor(s) (35 LLS C 371(c)(4))									
10.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT									
** 🗀	Article 36 (35 U.S.C. 371(c)(5)).	,								
Items	s 11 to 20 below concern document(s) or information included:	e/							
11.	An Information Disclosure Statemen	t under 37 CFR 1.97 and 1.98.								
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13.	A preliminary amendment.									
14. 🗀	An Application Data Sheet under 37 CFR 1.76.									
15. 📙	A substitute specification.									
16.	A power of attorney and/or change of									
17.	A computer-readable form of the se	quence listing in accordance with PCT Rule	13 <i>ter</i> .2 and 37 CFR 1.821- 1.825.							
18. 🗀	A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
19. 📙	A second copy of the English langua	age translation of the international application	n under 35 U.S.C. 154(d)(4).							
20.	Other items or information: Figure	1	. <u> </u>							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER				
10/535,522			PCT/EP2003/012941		100725-48 KGB				
	ng fees are submitted:								
a) Basic na	ational fee	\$							
b) Examin	ation fee	\$							
c) Search 1	fee	\$							
	TOTAL OF ABOVE CA	\$							
	ee for specification and d	_	1						
	O sheets of paper or frac		ronic medium). The fee is \$250	o for each					
Total Sheets	Extra sheets		umber of each additional 50 or fraction thereof (round up to a whole number)						
- 100 =	/50 =			× \$250.00	\$				
	30.00 for furnishing the or date (37 CFR 1.492(e)).	\$							
CLAIMS	NUMBER FII	_ED	NUMBER EXTRA	RATE	\$				
Total claims		- 20 =		× \$50.00	\$				
Independent clai	ims	- 3 =		× \$200.00	\$				
MULTIPLE DEP	ENDENT CLAIM(S) (if ap	+ \$360.00	\$						
		\$							
Applicant of by ½.	claims small entity status.	\$							
·			· <u></u>	SUBTOTAL =	\$				
•	of \$130.00 for furnishing t date (37 CFR 1.492(f)).	\$							
	·	\$							
	g the enclosed assignment to cover sheet (37 CFR 3.	\$							
			TOTAL FEES	ENCLOSED =	\$				
					Amount to be refunded:	\$			
		<u> </u>			Amount to be charged:	\$			
a. A chec	ck in the amount of \$		to cover the above f	ees is enclosed.					
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 14-1263 A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Kurt G. Brisco		3 /							
Customer No.		<u> </u>							
	ighlin & Marcus, P.A. enue - 18th Floor	coe							
New York, N		<i>y</i>							
		ON NUMBER							
		ON NUMBER							

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

Express Mail Label No. EV <u>627049635</u> US

Date: June 16, 2005

By: Jennifer Archer

Attorney Docket No. 100725-48 (KGB)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Alexander STEINKASSERER et al

SERIAL NO.

To Be Assigned [This is a 371 of PCT/EP2003/012941]

CUSTOMER NO. :

27384

FILED

Herewith

FOR

USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS

ENCODING THEM FOR THE TREATMENT OR PREBENTION

OF DISEASES

ART UNIT

To Be Assigned

EXAMINER

To Be Assigned

Commissioner for Patents PO Box 1450

Alexandria, VA 22313-1450

COMMUNICATION

Applicant requests that the attached sheet of drawing (Fig. 1, sheet 1 of 20) be made of record in the above identified application as it appears to have been inadvertently omitted from the specification.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

B

Kurt G. Briscoe

Attorney for Applicant(s)

Reg. No. 33,14/

875 Third Avenue - 18th Floor New York, New York 10022

Phone: (212) 808-0700 Fax: (212) 808-0844



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Alexander STEINKASSERER et al

SERIAL NO. : 10/535,522 [This is a 371 of PCT/EP2003/012941]

CUSTOMER NO. : 27384

FILED : May 18, 2005

FOR : USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS

ENCODING THEM FOR THE TREATMENT OR PREBENTION

OF DISEASES

EXAMINER : To Be Assigned

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number EV 627049635 US

Date of Deposit Scine 16, 2005

I hereby certify that the following items:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
Concerning a Submission Under 35 U.S.C. 371 – CHARGE DEPOSIT ACCOUNT

2. Communication

3. Figure 1

4. Return Receipt Postcard

are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

NORRIS, McLAUGHLIN & MARCUS, P.A.

Jennifer Archer